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ABSTRACT 
The FDA's Drug Manufacturing Inspection Compliance Program, which constitutes instructions to FDA personnel for conducting inspections, is 
a systems-based approach for inspections and is very consistent with the robust quality systems model presented in this guidance. The diagram 
below shows the relationship among the six systems: the quality system and the five manufacturing systems.  The quality system provides the 
foundation for the manufacturing systems that are linked and function within it. The quality systems model described in this guidance does not 
treat the five manufacturing systems as discrete entities, but instead integrates them into appropriate sections of the model. Those familiar with 
the six-system inspection approach will see organizational differences in this guidance; however, the inter-relationship. Generally, the term 
quality unit is used in this guidance.  However, quality control unit is used when directly quoting parts.  United States Food and Drug 
Administration (USFDA) propose Six System Inspection Model for the audit of pharmaceutical organization for minimization of regulatory 
submission. Author studied this system, then added and modified this to Eight System Inspection Model to make this more useful and user 
friendly for the pharmaceutical organization which wants to go for USFDA or other international audits. While doing this author added two 
additional systems (Management/Regulatory) and four additional points (Validation, HVAC System Validation, Water and Steam System 
Validation and Vendor Certification). 
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Introduction 
United States Food and Drug Administration (USFDA) in 
September 2004 announced pharmaceutical Current Good 
Manufacturing Practices (CGMP) for 21st century [1]. Their 
intention was to integrate quality system and risk 
management with existing CGMP guidelines to encourage 
adopting modern and innovative manufacturing technology. 
Also to harmonies the USFDA CGMP regulatory requirement 
with other international CGMP regulatory requirement [2, 3] 
and other quality management systems like International 
Standard Organization (ISO-9000) etc. The concept of 
Comprehensive Quality Management System (CQMS) is 
emerging from the USFDAs pharmaceutical CGMP for 21st 
century. The material in this paper is interpreted by the 
author from the Draft guidance for Industry Quality Systems 
Approach to Pharmaceutical CGMP Regulations [1]. 
Here, USFDA propose Six System Inspection Model for Food 
and Drug Administration (FDA) personnels for conducting 
inspection. By referring this model we developed Eight 
System Inspection Model which is a part of CQMS from the 
auditor and audittee or pharmaceutical organization point of 
view. It consists of two more systems i.e. 
regulatory/management and engineering. Here, we consider 
quality system as separate section which comprises the 
quality assurance and other quality related aspects. This 
system covers not only the 20 points referred by USFDA but 
also the other important aspects of CGMP i.e. 21 Code of 
Federal Regulations (CFR) Parts 210 & 211. 
The CQMS is designed to help manufacturer of 
pharmaceuticals to meet the requirements of the FDAs CGMP 
regulations and to reduce the frequent regulatory 
submissions for minor changes. The principal objective of 
CQMS is to ensure consistent production of a quality product 
(identity, strength, safety, purity & efficacy) and those 
activities are sustainable. The robust CQMS will promote 
process consistency by integrating effective knowledge 
building mechanism into daily operational decisions. 
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United States Food and Drug Administration (USFDA) in 
September 2004 announced pharmaceutical Current Good 
Manufacturing Practices (CGMP) for 21st century [1]. Their 
intention was to integrate quality system and risk 
management with existing CGMP guidelines to encourage 
adopting modern and innovative manufacturing technology. 
Also to harmonies the USFDA CGMP regulatory requirement 
with other international CGMP regulatory requirement [2] 
and other quality management systems like International 
Standard Organization (ISO-9000) etc. The concept of 
Comprehensive Quality Management System (CQMS) is 
emerging from the USFDAs pharmaceutical CGMP for 21st 
century. The material in this paper is interpreted by the 
author from the Draft guidance for Industry Quality Systems 
Approach to Pharmaceutical CGMP Regulations [1]. 
Here, USFDA propose Six System Inspection Model for Food 
and Drug Administration (FDA) personnels for conducting 
inspection. By referring this model we developed Eight 
System Inspection Model which is a part of CQMS from the 
auditor and audittee or pharmaceutical organization point of 
view. It consists of two more systems i.e. 
regulatory/management and engineering. Here, we consider 
quality system as separate section which comprises the 
quality assurance and other quality related aspects. This 
system covers not only the 20 points referred by USFDA but 
also the other important aspects of CGMP i.e. 21 Code of 
Federal Regulations (CFR) Parts 210 & 211. 
The CQMS is designed to help manufacturer of 
pharmaceuticals to meet the requirements of the FDAs CGMP 
regulations and to reduce the frequent regulatory 
submissions for minor changes. The principal objective of 
CQMS is to ensure consistent production of a quality product 
(identity, strength, safety, purity & efficacy) and those 
activities are sustainable. The robust CQMS will promote 
process consistency by integrating effective knowledge 
building mechanism into daily operational decisions. 
7 Critical FDA Concepts for Pharmaceuticals 
Quality Systems 
From the discovery of penicillin in the late 1920s to the 
breakthrough anti-cholesterol and anti-HIV drugs being 
manufactured today, the pharmaceutical industry has always 
been in the front line of developing new technologies. But the 
industry has yet to fully embrace modern quality systems 
operations. 
The FDA recently finalized a guidance to help pharmaceutical 
companies operate modern quality systems that are fully 
compliant with Current Good Manufacturing Practice 
(CGMP) regulations. The guidance is meant to encourage 
industry adoption of new technological advances and 
integrated quality systems, according to Dr. Janet Woodcock, 
FDA deputy commissioner and chief medical officer. The final 
guidance, which applies to manufacturing of drug products 
and components, was issued by the agency last September. 
Called “Guidance on Quality Systems Approach to 
Pharmaceutical CGMP Regulations,” the document is meant 
to bridge the gap between the 1978 CGMP regulations and 
current quality systems and risk management approach. By 
following the guidance, manufacturers will be able to make 
technological advancements in their operations more 
readily, with appropriate regulatory oversight. More 
importantly, the FDA is hoping that by following the 
guidance, manufacturers will be able to produce drugs more 
efficiently and at a lower cost. 
Seven critical concepts 
The guidance identifies seven concepts critical for modern 
quality systems: 
Quality: Refers to the strength, purity, and other quality 
characteristics meant to ensure a drug product’s safety and 
effectiveness. 
Quality by Design and Product Development: Designing 
and developing a product and associated manufacturing 
processes that will be used during product development to 
ensure that the product consistently attains a predefined 
quality. 
Quality Risk Management: This includes assessing the risks 
of quality issues, selecting and implementing risk 
management controls commensurate with the level of risk, 
and evaluating the results of the risk management efforts.  
Corrective Action and Preventive Action (CAPA): Focuses 
on investigating, understanding, and correcting 
discrepancies while trying to prevent their recurrence. 
Change Control: Managing change to prevent unintended 
consequences. 
Quality Unit: A group within an organization that promotes 
quality in general practice. 
Six-System Inspection Model: A model that can help 
pharmaceutical manufacturers comply with CGMP 
regulations. The six systems referred to in this inspection 
model are: quality, production, facilities and equipment, 
laboratory controls, materials, and packaging and 
labeling.[3] 
SIX SYSTEMS APPROACH TO PHARMACEUTICAL 
CGMP REGULATIONS 
The FDA has enacted several pharmaceutical cGMP 
regulations. These are key concepts that are critical to 
quality systems. Some of the concepts by which the FDA and 
other regulatory bodies ensure cGMP regulations are Quality, 
Quality by Design (QbD) and product development, Quality 
Risk Management, Corrective and Preventive Action (CAPA), 
Change Control, and the Six Systems Approach. [4], the six-
system inspection approach is a systems-based approach to 
cGMP and is aimed at ensuring a robust quality system 
model for pharmaceutical products.  Each of drug regulatory 
bodies across the world aspire practices to encourage and 
assist high-tech industries. Risk based prioritization in 
manufacturing inspections should instigate risk-based 
evaluation -making on a practical, each unit operation level 
throughout the manufacturing business. Implementation of 
the comprehensive Quality System Mode would ensure 
greater understanding of total operations leading to a more 
robust and updated Quality System that is fully compliant 
with cGMP regulations. 
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Six System Model [4-5] 
 
Fig 1: The diagram shows the correlation ship amongst the six systems: the quality system and the five manufacturing systems, 
which appear to be closely interrelated and inseparable during operations. 
The concepts of GMP do not treat the five manufacturing 
systems as discrete entities, but instead integrates them into 
appropriate sections interlinked with each other. The 
interrelationships between processes should be quite 
apparent. One of the important themes of the systems-based 
inspection compliance program is to be able to assess 
whether each of the systems is in a state of compliance. 
Pharmaceutical manufacturers should implement modern 
quality systems with risk management approaches to meet 
the requirements of the Agency's current good 
manufacturing practice (cGMP) as per regulations (2l CFR 
parts 210 and 211). The guidance based on comprehensive 
quality systems (QS) model, highlighting the model's 
consistency with the CGMP regulatory requirements for 
manufacturing human and veterinary drugs shall be of great 
help. 
1. Quality System:  
This system assures overall compliance with cGMP and 
internal procedures and specifications. The system includes 
the quality control unit and all of its review and approval 
duties (e.g., change control, reprocessing, batch release, 
annual record review, validation protocols, and reports, 
etc.). It includes all product defect evaluations and 
evaluation of returned and salvaged drug products. See the 
cGMP regulation, 21 CFR 211 Subparts B, E, F, G, I, J, and K.  
2. Facilities and Equipment System:  
This system includes the measures and activities which 
provide an appropriate physical environment and resources 
used in the production of the drugs or drug products. 
 It includes:  
a) Buildings and facilities along with maintenance;  
b) Equipment qualifications (installation and operation); 
equipment calibration and preventative maintenance; and 
cleaning and validation of cleaning processes as appropriate. 
Process performance qualification will be evaluated as part 
of the inspection of the overall process validation which is 
done within the system where the process is employed; and, 
 c) Utilities that are not intended to be incorporated into the 
product such as HVAC, compressed gases, steam and water 
systems.  See the cGMP regulation, 21 CFR 211 Subparts B, C, 
D, and J.  
3. Materials System: This system includes measures and 
activities to control finished products, components, 
including water or gases that are incorporated into the 
product, containers and closures. It includes validation 
of computerized inventory control processes, drug 
storage, distribution controls, and records.   
See the cGMP regulation, 21 CFR 211 Subparts B, E, H, 
and J.  
4. Production System: This system includes measures 
and activities to control the manufacture of drugs and 
drug products including batch compounding, dosage 
form production, in-process sampling and testing, and 
process validation. It also includes establishing, 
following, and documenting performance of approved 
manufacturing procedures.  See the cGMP regulation, 
21 CFR 211 Subparts B, F, and J.  
5. Packaging and Labeling System: This system 
includes measures and activities that control the 
packaging and labeling of drugs and drug products. It 
includes written procedures, label examination and 
usage, label storage and issuance, packaging and 
labeling operations controls, and validation of these 
operations.  See the cGMP regulation, 21 CFR 211 
Subparts B, G, and J.  
6. Laboratory Control System: This system includes 
measures and activities related to laboratory 
procedures, testing, analytical methods development 
and validation or verification, and the stability 
program.  See the cGMP regulation, 21 CFR 211 
Subparts B, I, J, and K. [6-7] 
Quality Systems 
Change management and change control 
Change control within quality management systems (QMS) 
and information technology (IT) systems is a formal process 
used to ensure that changes to a product or system are 
introduced in a controlled and coordinated manner. It 
reduces the possibility that unnecessary changes will be 
introduced to a system without forethought, introducing 
faults into the system or undoing changes made by other 
users of software. The goals of a change control procedure 
usually include minimal disruption to services, reduction in 
back-out activities, and cost-effective utilization of resources 
involved in implementing change. 
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Change control is currently used in various products and 
systems. For IT systems it is a major aspect of the broader 
discipline of change management. Typical examples from the 
computer and network environments are patches to 
software products, installation of new operating systems, 
upgrades to network routing tables, or changes to the 
electrical power systems supporting such infrastructure. 
Out of Specifications (OOS):- 
Out of Specification (OOS) means the test result that falls 
outside the specifications or acceptance criteria which has 
been specified in the official compendia monographs or the 
finished product. 
It provides agency’s current thinking on out of specification 
and test results. Purpose of this document is it includes 
results of all tests that fall under outside of the specification 
which are established in drug application, official compendia 
and drug master files or by the manufacturer. 
It also applies for all in process tests and chemistry based 
laboratory testing. Traditional testing and release methods 
are directed. Laboratory testing are performed under the 
active pharmaceutical ingredient, other components like in-
process materials and finished product materials apply to 
the extent of current good manufacturing practices 
regulation and food and drug cosmetic act 1. 
FDA Guidelines for OOS:- 
 This guidance covers the following: 
1. Finished products & active pharmaceutical ingredients 
 2. Biology and biotechnological products 
 3. Human drugs 
 4. Veterinary drugs 
 5. Combination of product 
 6. Type medicated articles  
7. Medicated feed 8. Dietary supplements 
 9. Transplantation of human tissues under 361 section out 
of specification in registration dossiers.  
Out of Trend (OOT):-  
OOT results are defined as a stability result that does not 
follow the expected trend, either in comparison with other 
stability batches or with respect to previous results collected 
during a stability study. 
A time dependent result which falls outside a prediction 
interval or fails a statistical process control criterion.  
A trend is a sequence of temporal procedures, e.g. for the 
manufacture of different batches of a product.  
Seven Critical Concepts of the FDA’s Quality Systems 
Guidance 
FDA Issues Final Guidance on Quality Systems Approach 
From the discovery of penicillin in the late 1920s to the 
breakthrough anti-cholesterol and anti-HIV drugs being 
manufactured today, the pharmaceutical industry has 
always been in the front line of developing new technologies. 
But the industry has yet to fully embrace modern quality 
systems operations. 
The FDA recently finalized a guidance to help 
pharmaceutical companies operate modern quality systems 
that are fully compliant with Current Good Manufacturing 
Practice (CGMP) regulations. The guidance is meant to 
encourage industry adoption of new technological advances 
and integrated quality systems, according to Dr. Janet 
Woodcock, FDA deputy commissioner and chief medical 
officer. The final guidance, which applies to manufacturing of 
drug products and components, was issued by the agency 
last September. 
Called “Guidance on Quality Systems Approach to 
Pharmaceutical CGMP Regulations,” the document is meant 
to bridge the gap between the 1978 CGMP regulations and 
current quality systems and risk management approach. By 
following the guidance, manufacturers will be able to make 
technological advancements in their operations more 
readily, with appropriate regulatory oversight. More 
importantly, the FDA is hoping that by following the 
guidance, manufacturers will be able to produce drugs more 
efficiently and at a lower cost. 
Basis of CQMS:- 
It is based on the philosophy that, 
“Quality should be built into the product, and testing alone 
cannot be relied on to ensure product quality.” 
This statement is supported by one incident which was 
happen with Boehringer Knoll Laboratories Ltd. There was 
production of an Antibacterial drug containing active 
ingredient as antibacterial agent along with other excipients. 
But due to failure in dispensing practice the dispensing 
officer dispensed Glibenclamide as one of the excipients 
along with antibacterial agent. In final Quality Control 
testing all test parameters were acceptable. But the incident 
of wrong addition of Glibenclamide came in focus, only after 
the complaints related to hypoglycemic effect are reported. 
This incident gives an idea that there are lots of such 
parameters which could not ensure the quality of product 
only by the final testing. That means the quality should be 
built through out the material and process flow and not only 
by the final testing of the product.[6] 
FDAs 20 points 
1. Provide leadership 
In developing robust quality management system, the higher 
authority or senior management has to define organizations 
mission and strategies. They have to take active 
participation in system design, implementation, monitoring 
and review, Committing necessary resources visibly support 
the quality system. They have to develop internal 
communication in the area of research development, 
regulatory affairs, manufacturing, quality unit, personnel 
and other related issues. 
2. Structure the organization 
When designing a CQMS, the management has the 
responsibility to define organizational structure and 
document it and also to determine the jobs (employee roles), 
responsibilities and authorities within the system, to 
empower employee to detect and resolve the problems 
affecting quality of product. 
3. Build your quality system to meet requirement 
The CQMs provide system help to ensure compliance within 
the regulations related to identity, strength, safety, purity 
and efficacy, to control the outsourcing. It also defines 
standards of quality (specifications) and implementation of 
quality policies. The developing, implementing, monitoring 
and revising quality procedures is one of the major aspects 
of CQMS 
4. Establish policies, objectives and plans 
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In developing CQMS, the senior management articulates 
their vision of quality through implementing the policies, 
objectives and plans. They provide strong commitment to 
quality into the organizational mission. They are responsible 
for developing quality manual, quality policies and to 
communicate policy at all levels of the organization, to make 
all employees and all other relevant people to understand it 
in letter and spirit also to revise these policies as and when 
needed. 
The Quality objectives are created at the top level of the 
organization (and other level as needed) through a formal 
quality planning process. Use quality planning process to 
identify resources and define methods to achieve the quality 
objectives. 
5. Review of the system 
System review is required to continuing suitability, 
adequacy and effectiveness of the robust quality system. 
Such review should typically include both, an assessment of 
the product as well as customer needs. The quality system 
review should cover the points like, quality policy and 
objectives, result of audit and other assessment, customer 
feed back including complaints, trend analysis, actions to 
prevent a potential problem or a recurrence, follow up 
action from previous management reviews. 
The review outcomes typically include improvements to the 
quality system and related quality processes, improvement 
to manufacturing processes and products, realignment 
resources. The review result must be recorded, planned 
actions should be implemented using corrective and 
preventive action and change control procedures. 
6. General arrangements of resources 
The following resources should be provided in adequacy, 
Building and facilities 
Equipment 
Materials 
Defined manufacturing and packaging process 
Facilities for laboratory analysis and related resources 
7. Develop personnel  
The CQMS recommends qualified and trained personnel to 
do an assigned work properly, without overruling the CGMP 
regulations. The senior management defines qualification for 
each position, also gives the training to personnel in CGMP 
and specific job. 
The training programmers should include at least following 
points, 
Identification of training needs 
Provision for training to satisfy their needs. 
Evaluation of effectiveness of training 
Documentation of training and retraining 
Use of skills learned in training, in day to day activities. 
8. Facilities and equipment  
FDA officers expertise can be used to identify and select the 
proper facilities and equipment. (Pre inspection approval 
may be sought). These facilities and equipment must be 
qualified, calibrated, cleaned and maintained to prevent 
contamination and mix-ups. Equipment should include both 
process as well as testing equipments i.e.  manufacturing, 
utilities and testing instruments or equipments etc. 
9. Control outsourced operations 
While outsourcing for operational processes to a second 
party, the Quality agreement should clearly describe 
materials and services, quality specifications responsibilities 
and communications mechanisms. Contract giver should 
satisfy him self about the adequacy and ability of the 
contract acceptors in terms of his quality systems and its 
implementation. 
10. Design and development of product and processes 
In CQMS the product characteristics are defined from design 
to delivery and exercise change control, and also the 
manufacturing, quality process and procedures are defined. 
It also establishes responsibilities for designing or changing 
products, documenting processes will ensure that critical 
variables are identified. This document should include 
resources and facilities needed, procedures to carry out 
processes, identification & control of critical variables, 
validation activities including operating ranges and 
acceptance criteria etc. 
11. Monitor packaging and labeling processes 
The CQMS recommend planning and documentation of all 
packaging and labeling procedures. These Procedures 
should outline Quality Control (QC) activities and 
responsible position, specifications and controls for 
packaging and labeling materials should also be determined 
before commercial production. 
In CQMS, a design plan should include authorities and 
responsibilities; design and development stages; and 
appropriate review, verification and validation. Change 
control should be maintained throughout the design process. 
12. Examine inputs 
In CQMS models, the term “input” refers to any materials 
that goes into a final product, no matter, whether it is 
traceable or not in the finished product and also whether the 
materials is purchased by the manufacturer or produced by 
the manufacturers for the purpose of processing. Materials 
can include items such as components (e.g. ingredients, 
process water etc).container and closures etc. Quality 
system should address receipt, production, storage and use 
of all products. 
All input must be tested or use of certificate of analysis of 
manufacturers may be accepted under suitable conditions. 
But even in the case of use of certificate of analysis, 
identification of the materials is needed. Materials produced 
in house should also go under the same acceptance criteria 
and testing procedures as other purchased materials (e.g. 
purified water, N2 gas etc.) 
13. Perform and monitor operations 
In the CQMS, areas of process weaknesses should be 
identified and factors that are influential on critical quality 
attributes should receive increased scrutiny. The process 
should be validated and sufficient testing data should be 
provided a system for continuous improvement of 
operations should be developed and implemented. The 
entire life-cycle should be addressed by the establishment 
for continuous improvement mechanism in the CQMS 
The procedure of review and evaluation should be in place 
to anticipate change control and monitor it. The deviations 
control procedures should also be in place. This deviation 
Jagtap et al                                                                                                                Journal of Drug Delivery & Therapeutics. 2019; 9(4):713-719 
 
ISSN: 2250-1177                                                                                   [718]                                                                                     CODEN (USA): JDDTAO 
control should cover personnel, materials, equipment and 
facilities. Product release record must be in place. 
The critical Process parameters monitored during 
production are as follows 
1. Process step should be verified by using validated 
computer system or a second person; these records 
must be maintained simultaneously. 
2. Procedures should be in place to prevent objectionable 
microorganisms in finished product that is not 
required to be sterile and to prevent microbial 
contamination of finished product purported to be 
sterile, sterilization process should be validated. 
3. The procedure should be developed to monitor, measure 
and analyses the operations 
4. Procedure should be in place to ensure the accuracy of 
test result. 
5. The system should address how to deal with “Out of 
Specifications” results. 
6. The CQMS should address product distributions issues. 
14. Address non conformities 
A key component in any CQMS is handling of non 
conformities / or deviations. It includes, Defining and 
classifying non conformities (e.g. Critical, Major  & Minor) 
Developing document system for identifications, 
investigation and corrective action to be taken against non 
conformities. 
Planed action for remedial purpose to avoid the recurrence 
in future and segregation of product currently facing non 
conformities. 
15. Analyze data for trends 
It involves collecting data from monitoring, measurement, 
complaint handling and other activities. This information is 
useful for detection and prevention of problems as early as 
possible. 
16. Conduct internal audits 
CQMS approach call for audits to be conducted at planned 
intervals to evaluate effective implementation and 
maintenance of the quality system and to determine if 
processes and products meet established parameters and 
specification. 
The entire system should at least be audited once the year in 
staggered or planned manner. The managers who are 
responsible for the areas audited to take timely actions to 
resolve audit findings and ensure that follow up actions are 
completed, verified and recorded. 
17. Risk assessment 
The management should assign priorities to activities or 
actions based on the consequence of actions or inaction 
otherwise known as risk assessment. The risk assessment is 
used as a tool in the development of product specifications 
and critical process parameters used in conjunction with 
process understanding, risk assessment helps anticipated, 
manage and control change. 
18. Corrective action 
The corrective action is a reactive tool for a system 
improvement to ensure that significant problems do not 
occur. The procedure is to be developed and documented to 
ensure that the need for action is evaluated relevant to the 
possible consequences, the root cause of the problem is 
investigated, possible actions are determined, selected 
action is taken within the defined time frame and 
effectiveness of the action taken is evaluated. It is essential 
to maintain records of corrective action taken. The 
management can gather information from following sources 
for taking corrective action, 
a. Nonconformance report and rejection 
b.Complaints 
C.Internal and External audit 
D.Data and risk analyses related to operation and quality 
system processes 
e.Management review decisions 
19. Preventive action 
The preventive action is an essential tool in quality system 
management. 
The Preventive action may involve areas like, succession 
planning, training, capturing institutional knowledge, 
planning for personnel, policy and process changes. The 
selected preventive action should be evaluated and recorded 
and the system should be monitored for the effectiveness of 
the actions 
20. Promote improvement 
The effectiveness of the quality system can be improved 
through the quality activities described as above in CQMS. It 
is critical that senior management be involved in the 
evaluation of this improvement process. 
AUTHORS POINTS 
1. Validation 
Initially pharmaceutical industry was heavily depended on 
controlling the quality, over a period of time this concept has 
changed to assuring the quality of product [3]. 
Pharmaceutical validation is the major activity under the 
quality assurance. Validation assures the desired 
performance of, 
Buildings 
Equipment 
Materials 
Processes etc 
Hence, without validation we can not think of assuring 
desired quality attributes in any product. 
2. Heating, Ventilation and Air conditioning (HVAC) 
system validation 
Air is one of the major constituent in the creating the desired 
environment including storage and processing. This 
environment includes requirements related to temperature, 
relative humidity, class of air, differential pressure; number 
of air changes etc. and this entire thing is taken care by a 
suitably designed, operated, monitored and maintained 
HVAC system. 
3. Water and steam system validation 
All the regulatory requirements including pharmacopoeia 
monographs give lot of importance to quality of 
pharmaceutical water. Particularly USP, not only describes 
different monographs on pharmaceutical water, but also 
describes in detail validation system for pharmaceutical 
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water. Pharmaceutical water is to be considered as one of 
the major raw materials particularly in case of most of the 
liquid formulations either sterile or non sterile. Hence, 
generation, storage, distribution, use and disposal of 
pharmaceutical water are considered as one of the major 
activity of assuring the quality of the pharmaceutical 
product and hence it is very important from point of view of 
regulatory compliance. 
4. Vendor certification 
USFDA and other drug regulatory authorities world over 
insist on consistency of quality of all the inputs into 
manufacturing of pharmaceutical product or hence, 
certification of vendors becomes a very important activity in 
assurance of quality of pharmaceutical product. One can 
depend on certified vendors for consistency of quality, 
commitment of deliveries and other technical & commercial 
aspects related to purchase of inputs. Vendor certification is 
a team activity, consisting of representative from purchase, 
quality assurance, production, Research and Development 
(R&D) and engineering etc. Hence, this activity must be 
considered as one of the major activity under quality 
assurance.[9]     
CONCLUSION 
While thorough study of this Six System Inspection Model 
the author found that the 20 points proposed by USFDA are 
not get appropriately fitted into the Six System Inspection 
Model. For this reason the author modified the 6/20 concept 
to 8/24 that means Eight System Inspection Model which 
not only covers all 20 points proposed by USFDA but also 
other 4 points which are very important and other 
regulations are also emphasized on this 4 points. 
In this Eight System Inspection Model, these 24 points fitted 
in such a way that it is found to be very useful for both 
Auditor and the Audittee i.e. pharmaceutical organizations. 
The pharmaceutical organizations which are going to be 
implementing the CQMS are found to prepare for the any 
type of audit that means either USFDA or any regional audit. 
One more and most important advantage of this CQMS is 
that, if in first inspection of USFDA, if FDA inspectors 
convinced that the CQMS is implemented and followed by 
the organization then in next inspection of USFDA they 
should remark that any small changes in facility, equipment 
or process etc are not required a regulatory submission after 
any small changes. 
For Auditor, this system is useful by means of reduction of 
time required for the inspection of pharmaceutical 
organization which can decrease the work load on the 
inspector and which is ultimately beneficial for the customer 
getting a quality product for distribution. 
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